Allergies News and Research

Latest Allergies News and Research

Benefits, quality gains of electronic referral management

Carefx Corporation, a leading provider of interoperable workflow solutions, announced today the availability of its new issue brief that outlines the benefits of electronic referral management – increased referral volume and revenue, enhanced clinical collaboration, simplified workflow and interoperability with health information exchange strategies.

16 Jun 2010

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Roughly half the world's population still lives in areas at risk of malaria transmission. Even in the United States, 1500 cases of malaria are reported annually on average.

15 Jun 2010

Scientists develop plastic antibody that works in bloodstream of living animal

Scientists are reporting the first evidence that a plastic antibody - an artificial version of the proteins produced by the body's immune system to recognize and fight infections and foreign substances - works in the bloodstream of a living animal. The discovery, they suggest in a report in the Journal of the American Chemical Society, is an advance toward medical use of simple plastic particles custom tailored to fight an array of troublesome "antigens."

10 Jun 2010

Diabetes expert uses TCOYD to empower people take active role in their condition

Now reaching epidemic proportions, diabetes has led to a significant increase in death and costly complications for approximately 26.2 million people nationwide. But diabetes expert and advocate Dr. Steven Edelman, diagnosed with diabetes at the age of 15, uses his non-profit organization and video series Taking Control of Your Diabetes to empower people to take an active role in their condition.

10 Jun 2010

2010 International Conference on Emerging Infectious Diseases at Atlanta, Georgia

Journalists are invited to attend and cover the 2010 International Conference on Emerging Infectious Diseases (ICEID), to be held July 11-14, 2010, at the Hyatt Regency, Atlanta, Georgia. The meeting is being organized by the Centers for Disease Control and Prevention (CDC), the American Society for Microbiology, the Council of State and Territorial Epidemiologists, the Association of Public Health Laboratories and the World Health Organization.

10 Jun 2010

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

10 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

Researchers decipher how mast cells set immune defense on right track

In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

8 Jun 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.

7 Jun 2010

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

New approach to treat RA can change lives of millions of patients: Research

Portuguese scientists have just published a revolutionary new approach to treat rheumatoid arthritis (RA) which, if translated to humans, can change the way we treat autoimmunity (and so diseases like RA but also diabetes and MS) and, with it, the lives of millions of patients.

3 Jun 2010

Allergies News and Research

Latest Allergies News and Research

Benefits, quality gains of electronic referral management

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Scientists develop plastic antibody that works in bloodstream of living animal

Diabetes expert uses TCOYD to empower people take active role in their condition

2010 International Conference on Emerging Infectious Diseases at Atlanta, Georgia

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

Boosting levels of ABCG1 protein in diabetics will improve insulin production

Researchers decipher how mast cells set immune defense on right track

La Jolla Institute scientist finds protein key to insulin secretion

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

New approach to treat RA can change lives of millions of patients: Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Allergies News and Research

Latest Allergies News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in